In 2021, semaglutide 2.4 mg became the most-effective GLP-1 RA approved for obesity management with 14.9% mean WL at 68 weeks vs. 2.4% with placebo [8]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.